The A1/A2 Casein Distinction: Implications for Dairy Protein Tolerance, Inflammation, and the Gut Microbiome

Eugene Capitano, DC, MSc in Neuroscience & Psychology of Mental Health – King's College London

Introduction: The Evolving Debate in Dairy Protein Nutrition

Dairy protein composition and genetic background have gained substantial attention in nutritional science, with a central focus on the distinctions between A1 and A2 β-casein in cow's milk and their downstream effects on health, particularly gut tolerance, inflammation, and the composition of the gut microbiome. Understanding these protein variants is critical not only for choosing whole dairy products but also for selecting processed dairy protein supplements like milk protein concentrate (MPC) and whey protein concentrate (WPC 80) (Jeong et al., 2023; Shukla et al., 2024).

Genetic Variants and Digestion: Why A1 Differs from A2

Among cow's milk proteins, β-casein comprises around 30% of the total protein and exists in at least 13 genetic variants, with A1 and A2 being the most prevalent. The A2 variant represents the ancestral form, while A1 emerged through a more recent mutation in European dairy breeds (Kaminski et al., 2007). The key distinction lies in the amino acid at position 67: proline in A2, but histidine in A1. This single substitution has major functional consequences: histidine at this site renders the peptide bond susceptible to enzymatic cleavage during digestion, resulting in the release of β-casomorphin-7 (BCM-7) from A1, whereas A2 resists this cleavage and produces little to no BCM-7 (Jeong et al., 2023; Kamiński et al., 2025).

BCM-7 is an opioid peptide with documented interactions at μ-opioid receptors in the gut and other tissues, potentially influencing gastrointestinal motility, immune modulation, and even neurochemical pathways (Jeong et al., 2023; Kamiński et al., 2025). Field and laboratory studies have shown that BCM-7 can delay gastrointestinal transit, increase gut inflammatory markers, and alter the

functional output of the microbiota, effects most pronounced in animal and in vitro studies but increasingly reported in humans as well (Gonzales-Malca et al., 2023; Kamiński et al., 2025). In susceptible individuals, BCM-7 (and by extension, A1 β-casein) may promote adverse gastrointestinal outcomes, including bloating, altered stool consistency, increased intestinal permeability, and low-grade inflammation (Jianqin et al., 2016; Choi et al., 2024; Song et al., 2025).

MPC vs. WPC 80: A1 Content and Tolerance

The distinction between A1 and A2 β-casein is highly relevant when comparing protein concentrates derived from milk (MPC) versus those derived from whey (WPC 80). MPC, as a concentrate of whole milk proteins, retains both the casein and whey fractions in proportions typical of cow's milk (roughly 80% casein, 20% whey). Unless specifically sourced from A2-certified herds, most commercial MPC will contain both A1 and A2 β-casein, especially when sourced from Holstein or other modern European breeds (Kamiński et al., 2025; Shukla et al., 2024).

In contrast, WPC 80 is a whey-dominant product, derived as the soluble protein fraction remaining after casein is removed during cheese making. This process effectively eliminates almost all casein protein, including both A1 and A2 variants, leaving a concentrate enriched in fast-digesting, low-allergenicity proteins such as β-lactoglobulin and α-lactalbumin (Barbano et al., 2010, Giribaldi et al., 2022). As a result, WPC 80 contains only trace amounts of casein and, by extension, a negligible amount of BCM-7–precursor peptides, making it functionally much more similar to an A2 dairy product than to conventional (A1-containing) MPC (Barbano et al., 2010; Giribaldi et al., 2022).

Gut Inflammation, Microbiome, and Systemic Health

A growing body of evidence implicates A1 β-casein, and specifically, BCM-7, in the promotion of low-grade gut inflammation and disruption of the intestinal microbiome, particularly in genetically or physiologically susceptible individuals (Jeong et al., 2023; Song et al., 2025; Kamiński et al., 2025).

BCM-7 can delay gut transit, increase gut permeability, and stimulate the mucosal immune system, leading to increased fecal calprotectin and other inflammation markers (Jianqin et al., 2016; Choi et al., 2024). Human crossover studies and randomized controlled trials have shown that regular ingestion of A1 β-casein is associated with greater symptoms of GI discomfort, prolonged transit, and increased inflammatory biomarkers. By contrast, switching to A2 milk or low-casein products like WPC 80 alleviates these symptoms and restores a healthier microbiome composition (Jianqin et al., 2016; Song et al., 2025; Choi et al., 2024).

Consumption of A2-only milk or casein-removed whey products supports increases in beneficial gut bacteria, most notably Bifidobacterium and Blautia, while decreasing bacteria associated with pro-inflammatory processes (Song et al., 2025; Jeong et al., 2023). These microbial shifts are associated with decreased fecal inflammation markers and improved epithelial barrier integrity (Song et al., 2025). These effects are partly due to the absence of casein-derived opioid peptides and partly to unique whey bioactive components, such as glycomacropeptide (GMP), which is prebiotic and anti-inflammatory (Arza et al., 2021; Dallas et al., 2023; Giribaldi et al., 2022).

Additionally, modern dietary patterns, characterized by frequent high-carbohydrate, high-glycemic foods and processed dairy (often rich in A1 β-casein or MPC), can synergistically worsen metabolic and gut health outcomes for sensitive individuals (Jeong et al., 2023; Song et al., 2025). The combination of high glycemic load with pro-inflammatory casein fractions may increase permeability, promote dysbiosis, and contribute to the systemic low-grade inflammation implicated in metabolic disease, mood disorders, and even autoimmune risk (Gonzales-Malca et al., 2023; Jeong et al., 2023). For individuals with compromised tolerance to A1 β-casein or dairy more generally, high amounts of MPC or regular milk as part of a Westernized, ultra-processed diet may amplify these negative effects and make them harder to discern (Kamiński et al., 2025; Jeong et al., 2023).

Broader Health Implications: Beyond the Gut

The benefits of transitioning from casein-rich, A1-containing MPC toward WPC 80 or A2-only protein sources may extend beyond the gut. Reduced gut inflammation and permeability support systemic immune balance, reduce allergy potential, and help optimize metabolic control (Kamiński et al., 2025; Barbano et al., 2010; Jeong et al., 2023). Some studies indicate that lowering BCM-7 exposure may reduce neuroinflammation and alleviate symptoms in certain neurodevelopmental and neuropsychiatric conditions, though more human data are needed (Shukla et al., 2024; Gonzales-Malca et al., 2023).

Whey and its main proteins, when concentrated and purified as in WPC 80, also offer proven benefits for muscle protein synthesis, glycemic control, and antioxidant status, advantages not offset by the negative BCM-7 effects associated with A1 casein (Barbano et al., 2010; Dallas et al., 2023; Jeong et al., 2023).

Practical Considerations

In summary, for individuals seeking to minimize gut inflammation, optimize microbiome integrity, and reduce systemic inflammatory burdens, whether due to genetic susceptibility, autoimmune risk, or pre-existing metabolic dysfunction, the choice of protein source is crucial. WPC 80, with its extremely low casein and negligible BCM-7 content, stands out as a better-tolerated, less inflammatory alternative to casein-rich products like MPC, especially those sourced without A2 certification (Barbano et al., 2010; Giribaldi et al., 2022; Jeong et al., 2023). This distinction becomes even more important in the context of modern diets dominated by high carbohydrate loads and processed dairy proteins. For those with known casein intolerance, functional GI symptoms, or a history of inflammatory disorders, prioritizing WPC 80 or true A2 dairy sources should be considered a foundational nutritional intervention (Jeong et al., 2023; Song et al., 2025; Shukla et al., 2024).

References

Arza, C. B., Cardozo-Filho, L., Lima, J. C., et al. (2021). Whey proteins are more efficient than casein in the recovery of muscle functional properties following a casting induced muscle atrophy. *PLoS ONE*, *8*(9), e75408.

Barbano, D. M., Zulewska, J., Newbold, M., Drake, M., & Evans, J. (2010). Comparison of composition and sensory properties of 80% whey protein and milk serum protein concentrates. *Journal of Dairy Science*, *93*, 1824–1843. https://doi.org/10.3168/jds.2009-2723

Choi, Y., Kim, N., Song, C. H., et al. (2024). The effect of A2 milk on gastrointestinal symptoms in comparison to A1/A2 milk: a single-center, randomized, double-blind, cross-over study. *Journal of Cancer Prevention*, *29*(2), 45–53. https://doi.org/10.15430/JCP.24.007

Dallas, D. C., et al. (2023). Macrophage-Immunomodulatory Actions of Bovine Whey Protein Isolate, Glycomacropeptide, and Their In Vitro and In Vivo Digests. *Nutrients*, *15*(23), 4942. https://doi.org/10.3390/nu15234942

Giribaldi, M., Lamberti, C., & Cavallarin, L. (2022). A2 milk and BCM-7 peptide as emerging parameters of milk quality. *Frontiers in Nutrition*, *9*, 842375. https://doi.org/10.3389/fnut.2022.842375

Gonzales-Malca, J. A., Tirado-Kulieva, V. A., Abanto-López, M. S., et al. (2023). Worldwide research on the health effects of bovine milk containing A1 and A2 β-casein: Unraveling the current scenario and future trends through bibliometrics and text mining. *Current Research in Food Science*, *6*, 100434.

Jeong, H., Park, Y. S., & Yoon, S. S. (2023). A2 milk consumption and its health benefits: an update. *Food Science and Biotechnology*, *33*, 491–503. https://doi.org/10.1007/s10068-023-01428-5

Jianqin, S., Leiming, X., Lu, X., Yelland, G. W., Ni, J., & Clarke, A. J. (2016). Effects of milk containing only A2 beta casein versus milk containing both A1 and A2 beta casein proteins on

gastrointestinal physiology, symptoms of discomfort, and cognitive behavior of people with self-reported intolerance to traditional cows' milk. *Nutrition Journal*, *15*, 35. https://doi.org/10.1186/s12937-016-0147-z

Kamiński, S., Cieślińska, A., & Kostyra, E. (2007). Polymorphism of bovine beta-casein and its potential effect on human health. *Journal of Applied Genetics*, *48*(3), 189–198.

Kamiński, S., & Cieślińska, A. (2025). β-Casein A1 and A2 genetic variants and β-casomorphin-7 in raw milk and processed milk products. *International Journal of Molecular Sciences*, *26*(8612), 1–15. https://doi.org/10.3390/ijms26218612

Shukla, N., Tripathi, A. K., Tiwari, A., et al. (2024). Decoding A1 and A2 milk: A thorough exploration. *International Journal of Agriculture Extension and Social Development*, *9*(1), 12–21.

Song, C.-H., Kim, N., Choi, Y., et al. (2025). Beneficial effect of consuming milk containing only A2 beta-casein on gut microbiota: A single-center, randomized, double-blind, cross-over study. *PLOS ONE*, *20*(5), e0323016. https://doi.org/10.1371/journal.pone.0323016